Navigation Links
Trovagene, Inc. Reports Third Quarter 2013 Financial Results
Date:11/14/2013

to common stockholders of $5.3 million, or $0.42 per share, for the nine months ended September 30, 2012. The increase in net loss available to common stockholders is primarily attributable to an increase in total operating expenses of $4.4 million, or $0.27 per share, and an increase in the change in fair value of derivative instruments related to warrants of $1.1 million, $0.07 per share, as compared to the prior year comparable period.

Cash and Cash Equivalents
Trovagene had cash and cash equivalents of approximately $28 million at September 30, 2013, as compared to $11 million at December 31, 2012. The Company completed a $15 million registered direct offering on July 31, 2013.

Review of Recent 2013 Announcements Demonstrate Progress in Development Programs

  • Presented first prospective cancer monitoring data demonstrating that Trovagene's diagnostics can detect rare oncogene mutation signals in urine that closely correlate to tissue biopsy and response to therapy.
  • Launched cell-free BRAF oncogene diagnostic, the first urine-based cancer mutation monitoring test.
  • Entered into collaboration with an undisclosed pharmaceutical company to study oncogene detection and monitoring in lung cancer. Initiated clinical collaboration with USC Norris Cancer Center to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.
  • Completed $15 million registered direct offering of common stock.
  • Webcast of Earnings Conference Call
    Trovagene's management team will host an earnings conference call on Thursday, November 14, 2013, at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time). Interested parties may listen to a live audio broadcast of the conference call on the Company's website in the Investor Room. A replay of the call can be accessed approximately one hour after the completion of the call and will be archived on the website for at least
    '/>"/>

    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
    2. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
    3. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    4. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    5. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    8. Pharmasset Reports Fiscal Year End 2011 Financial Results
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    10. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    11. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
    (Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
    (Date:2/26/2015)... Calif. , Feb. 26, 2015 Protiviti ... the latest version of the Governance Portal , ... governance, risk and compliance (GRC) tasks across multiple business ... been updated to help customers better align their controls ... the Treadway Commission ) requirements. In response to client ...
    (Date:2/26/2015)... February 26, 2015 The Movement for ... to support life extension technologies and awareness. The event ... Coordinated Time, on March 21st 2015, in a live ... , Eric Schulke, Founder of MILE, says, “Our lives ... urgency. The Movement for Indefinite Life Extension is raising ...
    Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
    ... a leader in human embryonic stem cell derived products, ... to produce induced pluripotent stem cells with Open Biosystems ... http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )In the spirit ... the complete and fully validated induced pluripotent stem cell ...
    ... Phase 2 MDCT Sub-study to be Released Concurrent with ... (Nasdaq: VIAP ), a biotechnology company focused ... cardiovascular and metabolic disease, today announced that an abstract ... has been accepted for a poster presentation at the ...
    ... today announced that it will host a conference call ... (FDA) approval of IXIARO(R), a new vaccine for the ... use of Intercell,s vaccine - the only such product ... adult travelers and military personnel who visit or are ...
    Cached Biology Technology:ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit 2VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009 2VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009 3VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009 4Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3
    (Date:2/24/2015)... YORK , Feb. 24, 2015 This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
    (Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
    (Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
    Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
    ... scientists have found a way to boost current industry capabilities ... coli 0157:H7 cells that may live undetected on spinach ... we can reduce the total number of foodborne pathogenic bacteria ... I professor of food science and human nutrition. According ...
    ... This press release is available in German . ... the most fascinating species of the Galapagos archipelago, treks ... the Max Planck Institute for Ornithology in Radolfzell, together ... and modern 3D acceleration measurements to find out that ...
    ... research delegation, Lund University and His Excellency the Ambassador of ... to a seminar dedicated to Swedish research on 5 December ... Brazil and present the latest research from Lund University. We ... decision makers, corporate organisations, as well as former and future ...
    Cached Biology News:Safer spinach? Scientist's technique dramatically reduces E. coli numbers 2Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3Swedish research useful to Brazilian society, presented by Lund University in São Paulo on 5 Dec. 2012 2Swedish research useful to Brazilian society, presented by Lund University in São Paulo on 5 Dec. 2012 3
    ... used technique for studying protein function and ... SDS-PAGE and transferred to a membrane such ... probed with specific antibodies. Unlike nucleic acid ... and Northern blots, it has been difficult ...
    ... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
    ... Introducing our Regulatory Edition of Molecular Imaging ... systems for life science research and drug ... compliance with U.S. Food and Drug Administrations ... 11 Electronic Records; Electronic Signatures [21 CFR ...
    ... is a 16 amino acid (amino acids 3-18) synthetic peptide ... The sequence of this peptide is (amino to carboxy terminus): ... V - K - L - R - A - ... K(18). This peptide may be used for neutralization ...
    Biology Products: